NURIX THERAPEUTICS IN

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

07 May 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Apr 2024 17:21:52 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

11 Apr 2024 22:38:26 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Proposed Public Offering

11 Apr 2024 15:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

10 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

09 Apr 2024 12:15:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

09 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

03 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

02 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

25 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

20 Mar 2024 08:40:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

11 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

06 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

15 Feb 2024 15:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

01 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

16 Jan 2024 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 15:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 11:00:00 By Nasdaq GlobeNewswire